About one third of the more than 118,000 people who received free skin cancer screenings from the AAD’s SPOTme program in 2009 and 2010 indicated they had recently seen a change in the size, shape or color of a mole.
Newer tools to help diagnose challenging lesions include combined immunohistochemical stains and a growing array of genetic tests, one of which has shown the potential to gauge metastatic risk.
Immune checkpoint inhibitors are providing rapid and durable responses for patients with metastatic Merkel cell carcinoma.
Melanoma’s burden is increasing and the rising rates cannot simply be attributed to increased disease detection, according to a research letter published last month in JAMA Dermatology.
The incidence of melanoma appears to be on the rise except for that observed in the younger population, underscoring a positive trend and hope for the fight against skin cancer.